G Bellastella1, M I Maiorino2, M Petrizzo3, A De Bellis4, A Capuano5, K Esposito6, D Giugliano2. 1. Endocrinology and Metabolic Diseases Unit, Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences, Second University of Naples, Piazza L. Miraglia 2, 80138, Naples, Italy. giuseppe.bellastella@unina2.it. 2. Endocrinology and Metabolic Diseases Unit, Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences, Second University of Naples, Piazza L. Miraglia 2, 80138, Naples, Italy. 3. IOS and Coleman Medicina Futura Medical Center, Centro Direzionale, Naples, Italy. 4. Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Naples, Italy. 5. Department of Experimental Medicine, Second University of Naples, Naples, Italy. 6. Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
Abstract
PURPOSE: To evaluate the Vitamin D status of patients with a single autoimmune disease and of patients with several autoimmune diseases. METHODS: We enrolled 35 patients with isolated type 1 diabetes mellitus (T1DM), 60 with autoimmune polyendocrine syndromes (APS) including T1DM and 72 control subjects. Among patients with APS, 10 were classified as type 2 (Addison's disease + T1DM), whereas the other 50 as type 3 (autoimmune thyroid disease + T1DM + other autoimmune diseases). Vitamin D (25-OHD) levels were assessed by a chemiluminescent immunoassay in all patients and controls on samples drawn in the morning of the same months. RESULTS: Both groups of APS and T1DM patients showed 25-OHD levels significantly lower than healthy controls (p < 0.001 for both vs controls), without any significant difference between the two groups (p = 0.80). The highest prevalence of vitamin D deficiency (values <20 ng/ml) was observed in APS type 3 subgroup (8 out of 50 patients, 16%). CONCLUSIONS: Patients with APS present reduced vitamin D circulating levels, but the vitamin D status is not different between patients with single or multiple autoimmune diseases. The kind of autoimmune disease, rather than the association of several autoimmune diseases, may influence negatively the levels of vitamin D. Further prospective studies are needed to clarify if impaired vitamin D level is a causal factor in the pathogenesis of autoimmune diseases or a consequence of them.
PURPOSE: To evaluate the Vitamin D status of patients with a single autoimmune disease and of patients with several autoimmune diseases. METHODS: We enrolled 35 patients with isolated type 1 diabetes mellitus (T1DM), 60 with autoimmune polyendocrine syndromes (APS) including T1DM and 72 control subjects. Among patients with APS, 10 were classified as type 2 (Addison's disease + T1DM), whereas the other 50 as type 3 (autoimmune thyroid disease + T1DM + other autoimmune diseases). Vitamin D (25-OHD) levels were assessed by a chemiluminescent immunoassay in all patients and controls on samples drawn in the morning of the same months. RESULTS: Both groups of APS and T1DM patients showed 25-OHD levels significantly lower than healthy controls (p < 0.001 for both vs controls), without any significant difference between the two groups (p = 0.80). The highest prevalence of vitamin D deficiency (values <20 ng/ml) was observed in APS type 3 subgroup (8 out of 50 patients, 16%). CONCLUSIONS:Patients with APS present reduced vitamin D circulating levels, but the vitamin D status is not different between patients with single or multiple autoimmune diseases. The kind of autoimmune disease, rather than the association of several autoimmune diseases, may influence negatively the levels of vitamin D. Further prospective studies are needed to clarify if impaired vitamin D level is a causal factor in the pathogenesis of autoimmune diseases or a consequence of them.
Entities:
Keywords:
Autoimmune polyendocrine syndromes; Type 1 diabetes mellitus; Vitamin D
Authors: Clifford J Rosen; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; JoAnn E Manson; Susan T Mayne; A Catharine Ross; Sue A Shapses; Christine L Taylor Journal: J Clin Endocrinol Metab Date: 2012-03-22 Impact factor: 5.958
Authors: Jacinto Orgaz-Molina; Agustín Buendía-Eisman; Miguel A Arrabal-Polo; José Carlos Ruiz; Salvador Arias-Santiago Journal: J Am Acad Dermatol Date: 2012-03-02 Impact factor: 11.527
Authors: Annamaria De Bellis; Elena Pane; Giuseppe Bellastella; Antonio A Sinisi; Caterina Colella; Roberta Giordano; Claudia Giavoli; Andrea Lania; Maria R Ambrosio; Carolina Di Somma; Maria C Zatelli; Emanuela Arvat; Annamaria Colao; Antonio Bizzarro; Antonio Bellastella Journal: Clin Endocrinol (Oxf) Date: 2011-09 Impact factor: 3.478
Authors: Elizabeth Buschur; Aruna V Sarma; Massimo Pietropaolo; Rodney L Dunn; Barbara H Braffett; Patricia A Cleary; Catherine Cowie; Mary E Larkin; Hunter Wessells; David M Nathan; Catherine Kim Journal: Diabetes Care Date: 2014-02 Impact factor: 19.112
Authors: Ahmet Nalbant; Ayhan Aydin; Alper Karacan; Attila Onmez; Ali Tamer; Hakan Cinemre Journal: Pak J Med Sci Date: 2017 Mar-Apr Impact factor: 1.088
Authors: Agnieszka Rusińska; Paweł Płudowski; Mieczysław Walczak; Maria K Borszewska-Kornacka; Artur Bossowski; Danuta Chlebna-Sokół; Justyna Czech-Kowalska; Anna Dobrzańska; Edward Franek; Ewa Helwich; Teresa Jackowska; Maria A Kalina; Jerzy Konstantynowicz; Janusz Książyk; Andrzej Lewiński; Jacek Łukaszkiewicz; Ewa Marcinowska-Suchowierska; Artur Mazur; Izabela Michałus; Jarosław Peregud-Pogorzelski; Hanna Romanowska; Marek Ruchała; Piotr Socha; Mieczysław Szalecki; Mirosław Wielgoś; Danuta Zwolińska; Arkadiusz Zygmunt Journal: Front Endocrinol (Lausanne) Date: 2018-05-31 Impact factor: 5.555